SUNSHINE BIOPHARMA INC (SBFM)
US8677816014 - Common Stock
Taking everything into account, SBFM scores 4 out of 10 in our fundamental rating. SBFM was compared to 565 industry peers in the Biotechnology industry. SBFM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SBFM is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year SBFM has reported negative net income.
SBFM had a negative operating cash flow in the past year.
SBFM had negative earnings in each of the past 5 years.
In the past 5 years SBFM always reported negative operating cash flow.
1.2 Ratios
SBFM has a Return On Assets of -14.06%. This is amongst the best in the industry. SBFM outperforms 84.34% of its industry peers.
With an excellent Return On Equity value of -16.88%, SBFM belongs to the best of the industry, outperforming 87.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.06% | ||
| ROE | -16.88% | ||
| ROIC | N/A |
ROA(3y)-224.14%
ROA(5y)-526.54%
ROE(3y)-2003.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SBFM (30.78%) is better than 74.91% of its industry peers.
SBFM's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SBFM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.86%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SBFM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SBFM has been increased compared to 1 year ago.
The number of shares outstanding for SBFM has been increased compared to 5 years ago.
There is no outstanding debt for SBFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -1.04, we must say that SBFM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SBFM (-1.04) is comparable to the rest of the industry.
There is no outstanding debt for SBFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.04 |
ROIC/WACCN/A
WACC10.91%
2.3 Liquidity
SBFM has a Current Ratio of 5.74. This indicates that SBFM is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SBFM (5.74) is comparable to the rest of the industry.
SBFM has a Quick Ratio of 3.57. This indicates that SBFM is financially healthy and has no problem in meeting its short term obligations.
SBFM has a Quick ratio (3.57) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.74 | ||
| Quick Ratio | 3.57 |
3. Growth
3.1 Past
SBFM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.76%, which is quite impressive.
The Revenue has grown by 61.94% in the past year. This is a very strong growth!
SBFM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 597.50% yearly.
EPS 1Y (TTM)84.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.83%
Revenue 1Y (TTM)61.94%
Revenue growth 3Y597.5%
Revenue growth 5YN/A
Sales Q2Q%41.6%
3.2 Future
SBFM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.50% yearly.
The Revenue is expected to grow by 110.76% on average over the next years. This is a very strong growth
EPS Next Y98.71%
EPS Next 2Y41.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year67.82%
Revenue Next 2Y110.76%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SBFM. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 3.97, which indicates a rather cheap valuation of SBFM.
98.93% of the companies in the same industry are more expensive than SBFM, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.78, SBFM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.97 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SBFM's earnings are expected to grow with 41.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.5%
EPS Next 3YN/A
5. Dividend
5.1 Amount
SBFM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SUNSHINE BIOPHARMA INC
NASDAQ:SBFM (12/23/2024, 6:24:41 PM)
After market: 2.92 -0.08 (-2.67%)3
+0.22 (+7.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.13%
Inst Owner Change-58.51%
Ins Owners0.17%
Ins Owner Change0%
Market Cap6.00M
Analysts82.86
Price Target306 (10100%)
Short Float %27.92%
Short Ratio0.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-70.97%
Min EPS beat(2)-110.24%
Max EPS beat(2)-31.69%
EPS beat(4)0
Avg EPS beat(4)-73.47%
Min EPS beat(4)-110.24%
Max EPS beat(4)-31.69%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.29%
Min Revenue beat(2)-29.92%
Max Revenue beat(2)1.34%
Revenue beat(4)3
Avg Revenue beat(4)0.12%
Min Revenue beat(4)-29.92%
Max Revenue beat(4)23.44%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1900%
EPS NY rev (1m)-126.75%
EPS NY rev (3m)-126.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.9%
Revenue NY rev (1m)-14.33%
Revenue NY rev (3m)-14.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.97 | ||
| P/S | 0.18 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.24 | ||
| P/tB | 0.27 | ||
| EV/EBITDA | N/A |
EPS(TTM)-150.88
EYN/A
EPS(NY)0.75
Fwd EY25.16%
FCF(TTM)-7
FCFYN/A
OCF(TTM)-5.91
OCFYN/A
SpS16.48
BVpS12.52
TBVpS11.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.06% | ||
| ROE | -16.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.78% | ||
| FCFM | N/A |
ROA(3y)-224.14%
ROA(5y)-526.54%
ROE(3y)-2003.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.86%
GM growth 5YN/A
F-Score4
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1089.73% | ||
| Cap/Sales | 6.63% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.74 | ||
| Quick Ratio | 3.57 | ||
| Altman-Z | -1.04 |
F-Score4
WACC10.91%
ROIC/WACCN/A
Cap/Depr(3y)579.51%
Cap/Depr(5y)350.71%
Cap/Sales(3y)3.43%
Cap/Sales(5y)3.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.83%
EPS Next Y98.71%
EPS Next 2Y41.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)61.94%
Revenue growth 3Y597.5%
Revenue growth 5YN/A
Sales Q2Q%41.6%
Revenue Next Year67.82%
Revenue Next 2Y110.76%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-322.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-256.5%
OCF growth 3YN/A
OCF growth 5YN/A